Loading...

MedXY AI/MedXY News/Tag: diabetes

MedXY News

EnglishTag

diabetes

59 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped associati

Section: CardiologyDec 25, 2025

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Section: Cardiology

Dec 23, 2025

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.

Section: Diabetes & EndocrinologyDec 17, 2025

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.

Section: Diabetes & EndocrinologyDec 14, 2025

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.

Section: Diabetes & EndocrinologyNov 18, 2025

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively norma

Section: Diabetes & EndocrinologyNov 5, 2025

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

Section: DermatologyNov 1, 2025

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults

Section: AIOct 29, 2025

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes sta

Section: CardiologyOct 20, 2025

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Section: Clinical UpdatesOct 9, 2025

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Section: CardiologyOct 8, 2025

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Section: Diabetes & EndocrinologyOct 7, 2025

Impact of Maternal Trace Element Levels on Neonatal Growth Among Diabetic and Non-Diabetic Pregnancies

Impact of Maternal Trace Element Levels on Neonatal Growth Among Diabetic and Non-Diabetic Pregnancies

A case–control study reveals that elevated copper levels in diabetic pregnant women negatively affect newborn weight and head circumference, while chromium correlates positively with birth length. Smoking exposure adversely impacts infants’

Section: Diabetes & EndocrinologyOct 6, 2025

Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases

Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases

A decade of research highlights cinnamon’s benefits in glycemic control, lipid modulation, anti-inflammatory effects, cognitive enhancement, and antimicrobial activity, supporting its adjunctive clinical use and revealing promising therapeu

Section: CardiologyOct 5, 2025

Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial

Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial

The PREVENT trial demonstrates that preventive PCI reduces adverse cardiac events in patients with vulnerable, non-flow-limiting coronary plaques, regardless of diabetes status, supporting a proactive interventional strategy alongside medic

Section: CardiologyOct 5, 2025

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

Section: Diabetes & EndocrinologyOct 5, 2025

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

The ADA’s 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.

Section: Diabetes & EndocrinologyOct 5, 2025

Global Impact of Cardiovascular Risk Factors on Lifetime Cardiovascular Disease Burden and Mortality: A Comprehensive Evidence Synthesis

Global Impact of Cardiovascular Risk Factors on Lifetime Cardiovascular Disease Burden and Mortality: A Comprehensive Evidence Synthesis

This review integrates data from over two million individuals globally, showing that absence of five key cardiovascular risk factors at age 50 confers a life expectancy advantage exceeding a decade, with midlife modification of hypertension

Section: CardiologyOct 5, 2025

Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects

Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects

This review synthesizes recent evidence on the benefits of high-intensity interval training (HIIT) on cardiovascular health, diabetes management, metabolic function, and neuroprotection, highlighting mechanistic insights and clinical implic

Section: CardiologyOct 4, 2025

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.

Section: Clinical UpdatesOct 3, 2025

Prev 1 2 3 Next